NIH Director's Pioneer Award FY2028 Forecast and FY2027 Reference
NIH has forecast the FY2028 Director’s Pioneer Award, with an estimated September 9, 2027 due date, but is not yet soliciting applications. This page explains the forecast and preserves FY2027 terms as historical reference; the full FY2028 announcement has not been published.
NIH Director’s Pioneer Award FY2028 Forecast and FY2027 Reference
Current status
The NIH Common Fund’s funding-opportunity page lists the NIH Director’s Pioneer Award Program as RFA-RM-28-001, with status “Forecasted. Not soliciting applications at this time.” The NIH page gives September 9, 2027 as an estimated application due date. Grants.gov identifies the record as a forecast for fiscal year 2028, with an estimated posting date of March 15, 2027, an estimated due date of September 9, 2027, an estimated award date of August 30, 2028, and an estimated project start of September 30, 2028. These are planning estimates, not an open application window, final dates, or authority to submit. NIH has not yet posted the full FY2028 notice of funding opportunity (NOFO) or its application package.
The forecast record estimates $8.2 million in total program funding and seven awards, and lists an award floor and ceiling of $700,000. These figures are forecast data. They do not establish the final award period or confirm that the FY2027 annual direct-cost structure will carry forward. The NIH program snapshot still describes the standing program as offering $700,000 in direct costs per year for up to five years, but only the eventual RFA-RM-28-001 NOFO can establish the terms for this competition. Applicants should not submit using the prior year’s package or assume that the coming round will retain its award terms.
The most recently completed full announcement covered the FY2027 competition, RFA-RM-27-001. Applications opened on August 9, 2026 and were due by 5:00 p.m. local time of the applicant organization on September 9, 2026. NIH stated that it would not accept late applications. That date has passed, so FY2027 is included here as a historical reference, while the page’s current status follows the separately forecast FY2028 round. The FY2027 announcement remains linked from NIH Common Fund’s funding opportunity page.
The FY2028 forecast lists broad categories of applicant organizations in Grants.gov, including non-domestic (foreign) entities. That is forecast-level organizational information, not a complete set of investigator-level eligibility conditions or restrictions; the full NOFO may refine or change it. This differs from the FY2027 NOFO, which excluded foreign organizations and non-U.S. components of U.S. organizations. The FY2027 single-investigator, career-stage, research-effort, and organizational rules below are clearly marked as prior-cycle terms; do not treat them as confirmed FY2028 requirements. Likewise, NIH has not yet published an FY2028 materials checklist or submission route. Check the official funding page and Grants.gov record for the full announcement and revisions before preparing an application. NIH recommends following its program updates and FAQ for changes.
The program’s purpose
The Director’s Pioneer Award is part of NIH’s High-Risk, High-Reward Research program, overseen by the NIH Common Fund. It is intended for individual scientists proposing bold, highly innovative research with the potential for broad impact on important problems relevant to NIH’s mission. Eligible scientific areas can span basic, translational, and clinical research. The emphasis is on the investigator’s creativity and the unusual significance and innovativeness of the proposed work.
NIH distinguishes a pioneering proposal from an ordinary extension of a productive research program. The proposed direction should be substantially different from work already underway in the investigator’s program and from research pursued elsewhere. It may build on the applicant’s experience, but should arise from a fundamental new insight, an exceptionally innovative approach, or a radically unconventional hypothesis. A larger sample, an expanded setting, or a straightforward scale-up alone does not make a project a fit.
The mechanism is designed to let research evolve. For the FY2027 competition, NIH did not request preliminary data or a detailed experimental plan. That flexibility did not remove the need to explain the important problem, why the concept represents a departure, what makes the investigator likely to pursue it effectively, and how the work would be conducted rigorously as it develops. The FY2028 notice may set different or more specific instructions; applicants must follow that future notice when it appears.
FY2027 award terms for reference
Under RFA-RM-27-001, NIH offered $700,000 in direct costs per year for up to five years, plus applicable indirect costs determined at award. The five-year direct-cost total was $3.5 million. NIH said it intended to commit approximately $8 million in FY2027 for about seven awards, subject to appropriations and the number of meritorious applications. Those were FY2027 estimates and terms; they are not confirmed for FY2028.
The FY2027 award could support basic, translational, or clinical research, and NIH-defined clinical trials were optional. A proposed clinical trial still had to address appropriate design, recruitment, safety, human-subject protections, analysis, and feasibility. The project period was limited to five years and the award was not renewable. NIH’s FAQ stated that an investigator could later receive another Pioneer Award only when its duration and research direction did not overlap with the earlier award.
FY2027 eligibility reference
The FY2027 call welcomed investigators at all career stages. Applications were for one Program Director/Principal Investigator; multiple-PI applications were not accepted. The institution submitted the application on the investigator’s behalf. NIH encouraged applications from the full spectrum of eligible institutions and backgrounds, but the organization had to meet the eligibility rules in the notice.
Non-U.S. organizations and non-U.S. components of U.S. organizations were ineligible under RFA-RM-27-001. Foreign components could be allowable under NIH policy, but foreign subawards or subcontracts were restricted by that notice. A U.S. applicant considering international collaborators needed to distinguish unpaid collaboration or permitted consulting from a prohibited foreign subaward and confirm the details with its sponsored research office. These conditions describe the FY2027 notice only; the forthcoming FY2028 announcement will control the next competition.
The FY2027 effort requirement was substantial. The investigator had to devote more than six person-months, or at least 51% of research effort, to the Pioneer project during the first three years. The minimum could decrease to four person-months (33%) in year four and three person-months (25%) in year five. Teaching, administrative, and clinical duties were not part of the research-effort calculation. Applicants with at least six person-months of existing research commitments had to explain how other commitments would be adjusted. Anyone using these figures for planning a future application should verify them against the new notice.
FY2027 application materials and submission
The FY2028 forecast is not an application package, and Grants.gov does not currently provide an application route for this forecasted opportunity. The instructions below describe only the completed FY2027 cycle. Do not submit with these forms or request FY2027 reference letters for a future round. Once NIH posts RFA-RM-28-001 as an active opportunity, the NOFO will name the accepted package, institutional submission options, registrations, and due-date rules.
For RFA-RM-27-001, the FY2027 application was submitted electronically by the eligible organization, not as a personal award application by the scientist. NIH accepted applications through ASSIST, Grants.gov Workspace, or an institutional system-to-system route, with submission tracking in eRA Commons. The organization needed active registrations, including the identifiers and accounts required by NIH and Grants.gov. NIH warned that registration could take weeks, so organizations preparing for a future round should confirm their process early. The precise package and systems instructions for FY2028 remain unannounced.
The central scientific narrative for RFA-RM-27-001 was an essay uploaded as a PDF named Essay.pdf. It asked applicants to explain the problem and its significance, the innovation and underlying insight, the project’s broad approach, the investigator’s record of innovation, why the project fit the Pioneer Award, and the required effort commitment. The essay was intentionally not a conventional detailed research plan. The notice did not request a Specific Aims page, preliminary data, or detailed budget forms.
The FY2027 application also included the PI’s biographical sketch and current-and-pending support information, plus a one-page facilities and other resources statement. Only the PI could be listed as senior or key personnel. Collaborators could be described in the essay, but their biosketches and letters of collaboration were not accepted. A data management and sharing plan was required when the work would generate scientific data; resource-sharing plans were expected as just-in-time information if an award was under consideration.
Each FY2027 PI had to arrange three, and only three, confidential reference letters. Referees submitted letters electronically through eRA Commons; applicants could not upload letters on their behalf or read them. Letters had to arrive by the deadline, and letters from prior years were not carried forward. NIH described the letters as evidence about the applicant’s creativity, scientific innovation, expertise, leadership, and ability to conduct independent research. This was a cycle-specific checklist; wait for the FY2028 notice before treating it as current.
FY2027 review timeline
The FY2027 NOFO listed an opening date of August 9, 2026, and a deadline of September 9, 2026, by 5:00 p.m. in the applicant organization’s local time. Its key-date table listed scientific merit review in March 2027, Advisory Council review in May 2027, and an earliest start date of July 2027. The same notice specified a proposed project period beginning September 1, 2027. NIH’s FAQ table gives August 2027 for award notifications and September 2027 as the earliest project start, so the published NIH materials differ on this point. All are dates for the closed FY2027 cycle; none establishes the schedule for FY2028.
For that application, corrected submissions also had to be received by the deadline; a late changed/corrected application was considered late. NIH advised applicants to inspect the application in eRA Commons and verify that it was complete and accurate. The new notice may specify a different sequence or dates, so prospective applicants should use the published FY2028 announcement rather than copy this timeline.
Preparing while FY2028 is forecast
While waiting for the full FY2028 announcement, investigators can assess whether their scientific premise fits the program without treating the forecast as authorization to apply. The posted forecast anticipates an estimated due date of September 9, 2027, but NIH may revise that date or the other estimates when it publishes the NOFO. Check the NIH funding-opportunity page and Grants.gov listing for status changes; until the status changes to an active opportunity and the application package is available, there is no FY2028 application to submit. Write down the difference between the proposed work and the lab’s current direction. Identify the central insight, what established assumption it challenges, and the consequence if the idea succeeds. If that distinction depends mainly on increasing scale or moving an existing method to a nearby problem, it may not meet the program’s stated concept of pioneering research.
Build the case from evidence about both the idea and the investigator. The FY2027 notice asked applicants to demonstrate a record of innovation, such as connecting fields, challenging paradigms, persisting through uncertainty, or carrying out difficult strategies. Specific examples are more useful than labels like “visionary.” The project should make its significance clear to readers beyond a narrow subfield while remaining scientifically coherent.
Institutional planning is also useful before the next notice appears. Discuss the effort commitment with the sponsored research office, identify registration lead times, and consider whether the institution can support the proposed work. If a project may involve a clinical trial or international collaboration, identify the relevant NIH policy questions early. Do not finalize budgets, letter requests, forms, or a submission calendar from the FY2027 details alone; confirm each instruction against RFA-RM-28-001 once NIH releases the full announcement.
Official sources and cycle notes
- NIH Common Fund: current and past Pioneer Award funding opportunities — lists RFA-RM-28-001 as forecasted and not currently soliciting applications, shows the estimated September 9, 2027 due date, and links the FY2027 announcement.
- Grants.gov forecast for RFA-RM-28-001 — lists the FY2028 forecast estimates for posting, due date, award date, project start, program funding, expected award count, and award floor/ceiling.
- RFA-RM-27-001 full announcement — authoritative terms and submission instructions for the historical FY2027 competition.
- NIH Common Fund Pioneer Award FAQ — program guidance, the FY2027 timeline, award details, and the expectation of a future funding opportunity.
- NIH Common Fund eligibility guide and application process guide — program guidance that supplements, but does not supersede, the applicable funding announcement.
The FY2027 RFA-RM-27-001 competition closed after its September 9, 2026 deadline; NIH’s funding-opportunity page now lists it among past opportunities. The September 9, 2027 date for RFA-RM-28-001 is an official estimate in the forecast, not a final deadline. NIH currently lists the FY2028 opportunity as forecasted and not soliciting applications, and the forecast record has no application package. A future round has therefore been announced at forecast level, but applicants cannot yet submit for FY2028. Its complete eligibility rules, award terms, application steps, and confirmed dates remain pending. Recheck NIH and Grants.gov for the full NOFO and application package before making application decisions.